Trump Eyes 250% Tariff on Indian Drugs: A Risky Move?

The President of the United States, Donald Trump, is known for his extremist policies, and in line with that, it is now being reported that he is proposing a 250% tariff on Indian pharmaceutical imports. This move is part of his broader attempt to dominate the global pharmaceutical market.

However, while this tariff imposition would initially hurt Indian drug suppliers, it could ultimately backfire and severely impact the United States itself.

Reportedly, India supplies 40% of the generic drugs used in the US, and such a steep tariff would make essential medications two to three times more expensive. This would significantly raise healthcare costs, especially for senior citizens and low-income patients.

It could also lead to drug shortages, as US manufacturers currently lack the capacity to make up for the shortfall. Hospitals would face serious strain, insurance premiums would increase, and there would likely be backlash from both patients and pharmaceutical companies in the US that rely heavily on Indian ingredients.

A prime example of the US dependence on Indian pharma was seen during the COVID-19 pandemic. When India imposed a temporary ban on hydroxychloroquine exports—then believed to help treat the virus—President Trump had to personally request Indian Prime Minister Narendra Modi to lift the ban, as the US did not have sufficient manufacturing capacity of its own.

If implemented, this tariff move could end up harming American citizens more than India. It could go down as one of the most misguided economic policies by a global leader, with Trump once again leaning toward extreme protectionist measures.